Development and validation of nomograms to predict survival of primary adrenal lymphoma: a population-based retrospective study

Abstract

While it is known that accurate evaluation of overall survival (OS) and disease-specific survival (DSS) for patients with primary adrenal lymphoma (PAL) can affect their prognosis, no stable and effective prediction model exists. This study aimed to develop prediction models to evaluate survival. This study enrolled 5448 patients with adrenal masses from the SEER Program. The influencing factors were selected using the least absolute shrinkage and selection operator regression model (LASSO) and Fine and Gray model (FGM). In addition, nomograms were constructed. Receiver operating characteristic curves and bootstrap self-sampling methods were used to verify the discrimination and consistency of the nomograms. The independent influencing factors for PAL survival were selected by LASSO and FGM, and three models were built: the OS, DSS, and FGS (DSS analysis by FGM) model. The areas under the curve and decision curve analyses indicated that the models were valid. This study developed survival prediction models to predict OS and DSS of patients with PAL. The FGS model was more accurate than the DSS model in the short term. Above all, these models should offer benefits to patients with PAL in terms of the treatment modality choice and survival evaluation.

Development and validation of nomograms to predict survival of neuroendocrine carcinoma in genitourinary system: A population-based retrospective study

“…Survival analysis often utilizes this method as one of the most frequently employed techniques for analyzing multiple variables. The initial proposition of the FGM in 1999, aimed at analyzing the distribution of a rival risk, enables the elimination of interference caused by competing events in survival analysis, leading to a survival model with enhanced accuracy [ 9 , 10 ].…”

Development and validation of nomograms to predict survival of primary cervical lymphoma: A surveillance, epidemiology, and end results (SEER) database analysis

“…They most often involve the gastrointestinal tract and skin but can occur in rare sites such as the breast, adrenal gland, testis, and female genital tract. [ 2 – 5 ] Primary lymphoma of the female genital tract (PLFGT) accounts for 0.2% to 1.1% of all non-Hodgkin lymphomas, [ 6 ] and the National Cancer Database reports that only 1.5% of extranodal non-Hodgkin lymphomas originate from the female genital tract, including the ovaries, uterus, cervix, vagina and vulva. [ 7 ] Studies have shown that the ovaries are the most common site of female genital tract lymphoma, [ 8 – 10 ] but others have shown that cervix is the most common one.…”